CN102423365A - Traditional Chinese drug composition for treating carotid atherosclerosis plaque - Google Patents
Traditional Chinese drug composition for treating carotid atherosclerosis plaque Download PDFInfo
- Publication number
- CN102423365A CN102423365A CN2011103956371A CN201110395637A CN102423365A CN 102423365 A CN102423365 A CN 102423365A CN 2011103956371 A CN2011103956371 A CN 2011103956371A CN 201110395637 A CN201110395637 A CN 201110395637A CN 102423365 A CN102423365 A CN 102423365A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- parts
- weight portions
- drug composition
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese drug composition for treating carotid atherosclerosis plaque. The traditional Chinese drug composition comprises the following raw materials, wherein the raw materials comprise, by weight, 30-60 parts of mongolian milkvetch root, 12-26 parts of dangshen, 12-24 parts of angelica, 10-18 parts of szechwan lovage rhizome, 16-30 parts of rehmannia dride rhizome, 12-30 parts of dan-shen root, 12-18 parts of safflower, 20-60 parts of peach seed and 12-40 parts of lobed kudzuvine root. The traditional Chinese drug composition has advantages of scientific and reasonable formula, definite therapeutic effect, easy taking, and definite anti-arteriosclerosis therapeutic effect. With the traditional Chinese drug composition, the atherosclerotic plaque can be effectively eliminated so as to reduce the incidence and the re-admission rate of cardio-cerebrovascular important events. All the components of the traditional Chinese drug composition are the pure traditional Chinese drugs, no significant adverse reaction is generated, the safety is high, and the patient compliance is good. Compared to other drugs for treating the atherosclerosis, the traditional Chinese drug composition of the present invention has the following advantages that: the price is low, the traditional Chinese drug composition is easy to widely use in the community hospitals and the primary hospitals, such that the economic burden of the patient family and the society can be reduced, and the practicality is provided in the drug economics field.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition of treating the carotid artery plaque.
Background technology
Carotid artery atherosclerosis plaques is the part of systemic atherosclerosis (AS), through modern medicine iconography technology for detection, can more accurately observe the carotid arterial atherosclerosis lesion degree, is regarded as the window of reflection whole body AS pathological changes.Carotid arterial atherosclerosis normal with existence simultaneously such as coronary artery, cerebral artery vessel, lesion degree has directly related property with cerebrovascular disease.Alleviate in early days and reverse carotid artery atherosclerosis plaques, can reduce the generation of apoplexy.
Atherosclerosis be a kind of be the complex lesions process of characteristic with the arterial wall accumulation of lipid, its initiating process mainly is absorption, participation and the activation of all kinds cell.Endothelial dysfunction; Blood fat and mononuclear cell enter gap under people's inner membrance; The monocytic cell ingests lipid is converted into macrophage, engulfs a large amount of lipids and forms foam cell, stimulated vascular smooth muscle cell propagation such as sedimentary lipid and the local cell that produces, somatomedin, inflammatory factor; And to the inner membrance migration, thereby cause atherosclerotic plaque to form.
Traditional medicine thinks, arteriosclerosis belong to ' blood stasis " category.Theory of Chinese medical science thinks that syndrome of blood stasis due to qi deficiency is the main pathological basis of senile disease, and with immunologic function disorder and thrombosis before state closely related.Body is empty with age, so the deficiency of common qi-blood-body fluid.Mostly senile disease patient's body constitution is deficient five internal organs, and with the deficiency of vital energy, suffering from a deficiency of the kidney is this, blood flows round without stopping in vascular.Depend on the promotion of gas, so-called " qi being the governor of blood ", " the capable then blood of gas is capable " promptly are.The deficiency of vital energy can not promote blood and in vascular, move, and the blood that is bound to is capable unable, and the slow or stasis of blood flow causes blood stasis.Its basic pathogenesis is deficiency of both QI and YIN, blood stasis due to qi deficiency.Hemorheology is generally acknowledged as one of objective indicator of syndrome of blood stasis.Blood stasis due to qi deficiency patient's QI and blood is mobile poor, and hemorheology index whole blood viscosity and blood plasma viscosity raise, erythrocyte electrophoretic time prolongs, and erythrocyte aggregation index raises.
Doctor trained in Western medicine comprises treatment by Chinese herbs and non-treatment by Chinese herbs in the method for treatment carotid artery atherosclerosis plaques.Non-treatment by Chinese herbs comprises that carotid artery intima strips off art, carotid stents angioplasty and optics chemistry carotid artery plasty, but difficulty is bigger, costs an arm and a leg, and has traumatic.Treatment by Chinese herbs mainly is to transfer fat, antiplatelet, antioxidation, but clinical effectiveness is unsatisfactory.
Summary of the invention
Technical problem to be solved by this invention provides a kind of Chinese medicine composition that can treat the carotid artery plaque, requires it to eliminate the effective of carotid artery plaque, and safety is good, and is cheap.
For solving the problems of the technologies described above; The invention provides a kind of Chinese medicine composition of treating the carotid artery plaque, comprise the raw material of following weight portion: the Radix Astragali 30-60 weight portions, Radix Codonopsis 12-26 weight portions, Radix Angelicae Sinensis 12-24 weight portions, Rhizoma Chuanxiong 10-18 weight portions, the Radix Rehmanniae 16-30 weight portions, Radix Salviae Miltiorrhizae 12-30 weight portions, Flos Carthami 12-18 weight portions, Semen Persicae 20-60 weight portions, Radix Puerariae 12-40 weight portions.
Further optimize as the present invention, the weight portion of said each raw material is: the Radix Astragali 30 weight portions, Radix Codonopsis 16 weight portions, Radix Angelicae Sinensis 12 weight portions, Rhizoma Chuanxiong 10 weight portions, the Radix Rehmanniae 16 weight portions, Radix Salviae Miltiorrhizae 12 weight portions, Flos Carthami 12 weight portions, Semen Persicae 20 weight portions, Radix Puerariae 12 weight portions.
For the purpose of the concise description problem, below the Chinese medicine composition of treatment carotid artery plaque according to the invention is all abbreviated as this compositions.
Modern pharmacological research shows, the expansible blood vessel of the Radix Astragali, brings high blood pressure down, strengthens myocardial contraction, and functions such as the interior free yl of removing and superoxide dismutase activity improving are arranged, and the Radix Astragali has the effect that strengthens cell vitality and resistance in addition.
Radix Codonopsis also has the effect of blood pressure regulation except that the enhancing human body immunity function is arranged.
Radix Angelicae Sinensis has the merit of enriching blood and invigorating blood circulation, and it has anticoagulant, antithrombotic formation, blood fat reducing, blood vessel dilating and hypotensive effect the modern pharmacology proof; Have vasospasm and contraction, superoxide dismutase is had remarkable activation.
Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Flos Carthami and Semen Persicae all have the merit that promoting flow of QI and blood, blood stasis dispelling stimulate the menstrual flow, and the pharmacology shows that they can improve hemorheology, blood vessel dilating, and anticoagulant, antithrombotic forms.Flos Carthami has antiinflammatory action, contains ligustrazine in the Rhizoma Chuanxiong, and its chemical constitution is a tetramethylpyazine; Be novel calcium antagonist, have effects such as blood vessel dilating, anticoagulant, blood viscosity lowering and inhibition smooth muscle cell proliferation, ischemic cerebral vascular is had prevention and therapeutical effect; Semen Persicae, Flos Carthami ability coronary blood flow increasing reduce myocardial oxygen consumption, microcirculation improvement; Anticoagulant; Anticoagulant the factor, improve inner skin cell function, restraining chronic inflammation process, promote collagen tissue to generate, regulate blood coagulable status, prevention thrombosis and promote thromboembolism etc., and expansible cerebrovascular; Improve the cerebral blood flow supply, prevent atherosclerosis and tissue abnormalities hypertrophy.
The Radix Rehmanniae: clearing away heat and cooling blood, YIN nourishing and the production of body fluid promoting has restraining chronic inflammation, improves the effect of inner skin cell function.
Radix Puerariae has blood sugar regulation, blood fat, and blood vessel dilating suppresses Renin-Angiotensin System, the effect of bringing high blood pressure down.
This compositions is reused the Radix Astragali as monarch drug, tonifying QI to promote blood circulation; Radix Codonopsis close the Radix Astragali then the merit benefit of air making-up and spleen enlivening show, Rhizoma Chuanxiong closes Radix Astragali promoting flow of QI and blood, is all ministerial drug; The deficiency of vital energy can not promote blood and in vascular, move, and the blood that is bound to is capable unable, and the slow or stasis of blood flow causes blood stasis.Chinese angelica blood supplementing is invigorated blood circulation, the Radix Rehmanniae, Radix Puerariae YIN nourishing and the production of body fluid promoting, and Radix Salviae Miltiorrhizae, Flos Carthami, Semen Persicae blood circulation promoting and blood stasis dispelling, tonify without causing stagnation are adjuvant drug all, play benefiting QI for activating blood circulation, eliminate the effect of speckle.
Therefore; Thereby this compositions has benefiting qi and nourishing blood, blood circulation promoting and blood stasis dispelling, dilution thickness blood, keeps the blood vessel normal function, suppresses smooth muscle cell proliferation, makes stream minimizing inhibition lipoxidase activity in the calcium; OxLDL ELISA is formed to be reduced; Have the effect of protection blood vessel endothelium blood lipid regulation simultaneously, reduce foam cell formation amount, so have the effect of removing atheromatous plaque.
This compositions has prescription science, rationally, determined curative effect, and taking convenience, the advantage of the effect determined curative effect of arteriosclerosis can effectively be eliminated atheromatous plaque, thereby reduces the incidence rate and the admission rate again of the critical event of cardiovascular and cerebrovascular vessel.This compositions component all is pure Chinese medicine, no obvious adverse reaction, and safe, patient's compliance is better.With respect to other treatment atherosclerosis medicine relatively, cheap, be convenient to community and basic hospital and be widely used, can alleviate the financial burden of patient family and society, have more practicality from the pharmacoeconomics aspect.
Each component of this compositions all can be buied on market.
This compositions water taken after fried promptly can be used for treating the carotid artery plaque.
For further specifying the effect of this compositions, explain with control experiment at present.
One, experiment condition and grouping:
The 58 routine patients that alternative condition is similar; Through the outstanding colorful Doppler ultrasound diagnostic apparatus of PHILIPS (frequency probe 10.0MHZ) detect to confirm carotid artery intima-middle level thickness thicken with (or) outpatient service or inpatient that speckle forms, get rid of severe cardiac, liver, kidney disease patient.
The concrete grouping: carotid artery atherosclerosis plaques patient is totally 58 examples (male 32 examples, women 26 examples), age 60-78 year, average 69.4 soil 8.8 years old.Be divided into two groups at random: 29 examples (male 17 examples, women 12 examples) are organized in treatment, age 61-77 year, average 69.1 scholars 7.9 years old, complication with diabetes 18 examples wherein, complicated hypertension 14 examples.Matched group 29 examples, male 15 examples, women 14 examples, age 60-78 year, average 68.6 scholars 8.0 years old, complication with diabetes 19 examples wherein, complicated hypertension 13 examples.Two groups of ages, sex, the equal not statistically significant of concurrent underlying diseases difference (P>0.05).
Two groups according to conventional resisting hypertension, blood sugar lowering or the antiplatelet drug used of the state of an illness.It is oral that the treatment group gives this compositions (Radix Astragali 30 grams, Radix Codonopsis 16 grams, Radix Angelicae Sinensis 12 grams, Rhizoma Chuanxiong 10 grams, the Radix Rehmanniae 16 grams, Radix Salviae Miltiorrhizae 12 grams, Flos Carthami 12 grams, Semen Persicae 20 grams, Radix Puerariae 12 grams, Radix Glycyrrhizae 6 grams) decoct in addition; Each 200 milliliters; Take twice every day, every day potion.
The course of treatment: 8 weeks were 1 course of treatment.Statistical result after 1 course of treatment.
Two: observation item:
1, carotid ultrasound is measured: adopt the outstanding colorful Doppler ultrasound diagnostic apparatus of PHILIPS, frequency probe 10.0MHZ.Special messenger's operation.The patient gets dorsal position; Portraitlandscape cooperates scanning; Measure bilateral carotid (CCA) respectively, the size of media thickness (IMT) and lumen diameter in the internal carotid artery (ICA), each blood vessel of external carotid artery (ECA); Observe size, form, echo, the scope of speckle and have or not narrow and obstruction, the person measures the internal diameter stenosis rate to have the speckle.Plaque thickness is inner membrance-lumen of artery interface to the distance of China and foreign countries' membrane interface, often is standard with the rear wall, and same position is measured respectively 3 times, averages to be carotid intimal medial thickness, IMT>1.0 mm promptly are called atheromatous plaque and thicken.
2, diligent generation Supreme Being R80A fully automatic blood rheometer measurement whole blood height is cut viscosity number, low viscosity number, plasma viscosity, the packed cell volume cut of whole blood in the employing.All object of study are drawn blood and were prohibited high fat diet, venous blood samples after fasting 8-12 hour in preceding 3 days.
Relatively adopt paired t-test before and after the treatment.
Three, observed result:
1, relatively (X ± s) (specifically see table 1), treatment back treatment group hemorheology all obviously improves the hemorheology before and after treatment group and the treatment of control group, and significant difference (P < 0.05) is relatively arranged, and notable difference (P < 0.05) is more also arranged between group.
Table 1: the hemorheology comparison before and after treatment group and the treatment of control group (X ± s)
2, measure treatment rear neck artery blood vessels caliber, interior-media thickness, speckle size before and after the treatment.Significant difference (P < 0.05) is relatively arranged before and after the treatment group treatment.Matched group is there was no significant difference relatively.Specifically see table 2.
Table 2: carotid artery vascular caliber before and after the treatment, interior-media thickness, speckle size be (X ± s) relatively
3, all patients that take this compositions do not have an example that untoward reaction takes place.
Four, conclusion:
With compare before the treatment, treatment group treatment back hemorheology obviously improves, in the carotid artery in the obvious attenuation of film, the carotid artery plaque dwindles or disappears, compares with matched group that there were significant differences, and statistical significance is arranged.
In sum, this compositions is eliminated the effective of carotid artery plaque, and safety is good, and is cheap.
The specific embodiment
Further specify the present invention through embodiment below.
Embodiment 1:
The Chinese medicine composition of treatment carotid artery plaque, every dose of raw material that comprises following weight portion: Radix Astragali 30g, Radix Codonopsis 16g, Radix Angelicae Sinensis 12g, Rhizoma Chuanxiong 10g, Radix Rehmanniae 16g, Radix Salviae Miltiorrhizae 12g, Flos Carthami 12g, Semen Persicae 20g, Radix Puerariae 12g.
Instructions of taking: decoct is oral, each 200 milliliters, take twice every day, every day potion.8 weeks were 1 course of treatment.
Embodiment 2:
The Chinese medicine composition of treatment carotid artery plaque, every dose of raw material that comprises following weight portion: Radix Astragali 60g, Radix Codonopsis 26g, Radix Angelicae Sinensis 24g, Rhizoma Chuanxiong 18g, Radix Rehmanniae 20g, Radix Salviae Miltiorrhizae 25g, Flos Carthami 18g, Semen Persicae 50g, Radix Puerariae 40g.
Instructions of taking: decoct is oral, each 200 milliliters, take twice every day, every day potion.8 weeks were 1 course of treatment.
Embodiment 3:
The Chinese medicine composition of treatment carotid artery plaque, every dose of raw material that comprises following weight portion: Radix Astragali 40g, Radix Codonopsis 12g, Radix Angelicae Sinensis 20g, Rhizoma Chuanxiong 14g, Radix Rehmanniae 30g, Radix Salviae Miltiorrhizae 30g, Flos Carthami 16g, Semen Persicae 60g, Radix Puerariae 26g.
Instructions of taking: decoct is oral, each 200 milliliters, take twice every day, every day potion.8 weeks were 1 course of treatment.
This Chinese medicine composition can carry out the increase and decrease of each component and weight portion according to the state of an illness in practical application.
Above-described only is three embodiments of the present invention.Should be pointed out that for the person of ordinary skill of the art under the prerequisite that does not break away from the principle of the invention, can also make some modification and improvement, these also should be regarded as belonging to protection scope of the present invention.
Claims (2)
1. treat the Chinese medicine composition of carotid artery plaque, comprise the raw material of following weight portion: the Radix Astragali 30-60 weight portions, Radix Codonopsis 12-26 weight portions, Radix Angelicae Sinensis 12-24 weight portions, Rhizoma Chuanxiong 10-18 weight portions, the Radix Rehmanniae 16-30 weight portions, Radix Salviae Miltiorrhizae 12-30 weight portions, Flos Carthami 12-18 weight portions, Semen Persicae 20-60 weight portions, Radix Puerariae 12-40 weight portions.
2. the Chinese medicine composition of treatment carotid artery plaque according to claim 1 is characterized in that: the raw material that comprises following weight portion: the Radix Astragali 30 weight portions, Radix Codonopsis 16 weight portions, Radix Angelicae Sinensis 12 weight portions, Rhizoma Chuanxiong 10 weight portions, the Radix Rehmanniae 16 weight portions, Radix Salviae Miltiorrhizae 12 weight portions, Flos Carthami 12 weight portions, Semen Persicae 20 weight portions, Radix Puerariae 12 weight portions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103956371A CN102423365A (en) | 2011-12-03 | 2011-12-03 | Traditional Chinese drug composition for treating carotid atherosclerosis plaque |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103956371A CN102423365A (en) | 2011-12-03 | 2011-12-03 | Traditional Chinese drug composition for treating carotid atherosclerosis plaque |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102423365A true CN102423365A (en) | 2012-04-25 |
Family
ID=45957452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103956371A Pending CN102423365A (en) | 2011-12-03 | 2011-12-03 | Traditional Chinese drug composition for treating carotid atherosclerosis plaque |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102423365A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103393805A (en) * | 2013-07-31 | 2013-11-20 | 山东省立医院 | Chinese medicinal composition |
| CN112007119A (en) * | 2020-10-14 | 2020-12-01 | 上海中医药大学附属岳阳中西医结合医院 | Traditional Chinese medicine composition for treating carotid arteriosclerosis and application thereof |
| CN112791150A (en) * | 2021-02-01 | 2021-05-14 | 湖南泓瑞中药饮片有限公司 | Traditional Chinese medicine composition for treating neck vascular plaque and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1476849A (en) * | 2002-08-21 | 2004-02-25 | 韩海龙 | Medicine composition for promoting blood circulation and removing stasis |
| CN1857510A (en) * | 2006-03-28 | 2006-11-08 | 王福正 | Medicine for treating coronary heart disease |
| CN101002899A (en) * | 2007-01-11 | 2007-07-25 | 许新华 | Pure traditional Chinese medicine preparation for treating hemiparalysis |
-
2011
- 2011-12-03 CN CN2011103956371A patent/CN102423365A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1476849A (en) * | 2002-08-21 | 2004-02-25 | 韩海龙 | Medicine composition for promoting blood circulation and removing stasis |
| CN1857510A (en) * | 2006-03-28 | 2006-11-08 | 王福正 | Medicine for treating coronary heart disease |
| CN101002899A (en) * | 2007-01-11 | 2007-07-25 | 许新华 | Pure traditional Chinese medicine preparation for treating hemiparalysis |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103393805A (en) * | 2013-07-31 | 2013-11-20 | 山东省立医院 | Chinese medicinal composition |
| CN103393805B (en) * | 2013-07-31 | 2015-01-07 | 山东省立医院 | Chinese medicinal composition |
| CN112007119A (en) * | 2020-10-14 | 2020-12-01 | 上海中医药大学附属岳阳中西医结合医院 | Traditional Chinese medicine composition for treating carotid arteriosclerosis and application thereof |
| CN112007119B (en) * | 2020-10-14 | 2022-06-28 | 上海中医药大学附属岳阳中西医结合医院 | Traditional Chinese medicine composition for treating carotid arteriosclerosis and application thereof |
| CN112791150A (en) * | 2021-02-01 | 2021-05-14 | 湖南泓瑞中药饮片有限公司 | Traditional Chinese medicine composition for treating neck vascular plaque and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xu et al. | Guidelines for diagnosis and treatment of hepatic fibrosis with integrated traditional Chinese and Western medicine (2019 edition) | |
| CN102688472B (en) | Medicinal composition for preventing or relieving yang deficiency syndrome of tumor patient | |
| CN102423365A (en) | Traditional Chinese drug composition for treating carotid atherosclerosis plaque | |
| CN102423423B (en) | Traditional Chinese medicine for treating urinary tract infection | |
| CN103330826A (en) | Traditional Chinese medicine composition for treating deficiency of lung yin | |
| CN103191204B (en) | Medicine composite for treating chronic kidney diseases and preparation method and application of medicine composite | |
| CN105596777A (en) | Traditional Chinese medicine for dredging blood vessels and reducing blood pressure | |
| CN108079250A (en) | A kind of herbal composite for treating the proliferation of mammary gland | |
| CN102293842B (en) | Preparation for treating ulcerative colitis and preparation method thereof | |
| CN104435519A (en) | Pharmaceutical composition for treating primary dysmenorrhea | |
| CN101229345B (en) | Qi-replenishing and blood-enriching medicine | |
| CN103948782A (en) | Pharmaceutical composition for treating hyperplasia of mammary glands due to stagnation of liver qi as well as preparation method and application of pharmaceutical composition | |
| CN102861159B (en) | Medicine composition for treating dysmenorrheal as well as preparation method and application thereof | |
| CN102552736A (en) | Traditional Chinese medicine composition for treating idiopathic thrombocytopenic purpura | |
| CN101596302A (en) | A kind of treatment treating coronary heart disease and angina pectoris and preparation method thereof | |
| CN103845580A (en) | Traditional Chinese medicine composition for treating allergic rhinitis | |
| CN103099896B (en) | Herb tea for treating cardiovascular and cerebrovascular diseases | |
| CN104740579B (en) | Premenstrual peace piece and its preparation technology | |
| CN104127752B (en) | Treat the Chinese medicine of affection of exogenous wind-heat type glomerulonephritis blood urine | |
| CN104740291A (en) | Traditional Chinese medicine for treating rheumatic heart disease | |
| CN103768439A (en) | Traditional Chinese medicinal composition for regulating endocrine as well as formulation and preparation method thereof | |
| CN106038812A (en) | Traditional Chinese medicine capsule for reducing blood fat and removing atherosclerotic plaque | |
| CN102824611B (en) | Traditional Chinese medicine for treating menstrual disorder | |
| CN112516213B (en) | Yao medicine composition, decoction and capsule for treating gallstone and application thereof | |
| CN102416036B (en) | Traditional Chinese medicinal compositions for preventing and treating ventricular reconstruction due to coronary heart disease and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120425 |